"Menopause and the effects of hot flashes in particular are without a doubt one of the most significantly important health issues facing many women today, and as a result, the opportunity to provide women with a safe and effective treatment to reduce or eliminate hot flash symptoms is enormous," stated Michael Borkowski, CEO of Eaton Scientific. "Traditional hormone treatments have been shown to cause a dramatic increase in the risk of breast cancer and cardiovascular disease. Improved awareness of these health risks has led to a high unmet demand for non-hormonal treatment options. As a result, novel non-hormonal treatments such as Tropine 3 are poised to overtake traditional hot flash treatments."

In 2010, the women's health therapeutics market was calculated to be worth approximately $14.5 billion. GBI Research, a leading business intelligence provider, forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 7.9% between 2010 and 2017 to record a sales value of approximately $24.7 billion in 2017. Novel non-hormonal therapeutics such as Tropine 3 are expected to become increasingly popular during the forecast period. Based on current and expected market conditions, the Company estimates that Tropine 3, if successfully tested and promoted, has a global market potential in excess of $500 million in annual sales.

The Company is currently finalizing arrangements for conducting Phase 1 & 2 clinical trials of Tropine 3 with the goal of final FDA approval. Additional information regarding clinical trial start dates will be made available shortly.

About Pristine Solutions, Inc.

Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women. The company is preparing for Phase 1 & 2 Clinical Trials with the goal of FDA approval of Tropine 3.

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.